Glicklich Alan 4

4 · ADURO BIOTECH, INC. · Filed Oct 7, 2020

Form 4

Period: 2020-10-05

Chief Medical Officer

Transactions

Award
Stock Option (right to buy)
2020-10-06+62,660→ 62,660 total
Exercise: $14.77Exp: 2030-10-05→ Common Stock (62,660 underlying)
Award
Restricted Stock Units (RSU) (Common Stock)
2020-10-06+21,311→ 21,311 total
Exp: 2030-10-05→ Common Stock (21,311 underlying)
Award
Stock Option (right to buy)
2020-10-05+242,662→ 242,662 total
Exercise: $0.42Exp: 2030-04-21→ Common Stock (242,662 underlying)

Footnotes (5)

[F1]The stock option vests as to 25% of the total shares on April 20, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F2]Received in connection with the merger of Private Chinook into the Issuer in exchange for a stock option to acquire 830,500 shares of Private Chinook common stock for $0.12 per share.
[F3]The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F4]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
[F5]The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date.

Documents

1 file